J Clin Invest. 2013 Nov;123(11):4809-20. doi: 10.1172/JCI64578.
The prevention and treatment of acute chest syndrome (ACS) is a major clinical concern in sickle cell disease (SCD). However, the mechanism underlying the pathogenesis of ACS remains elusive. We tested the hypothesis that the hemolysis byproduct hemin elicits events that induce ACS. Infusion of a low dose of hemin caused acute intravascular hemolysis and autoamplification of extracellular hemin in transgenic sickle mice, but not in sickle-trait littermates. The sickle mice developed multiple symptoms typical of ACS and succumbed rapidly. Pharmacologic inhibition of TLR4 and hemopexin replacement therapy prior to hemin infusion protected sickle mice from developing ACS. Replication of the ACS-like phenotype in nonsickle mice revealed that the mechanism of lung injury due to extracellular hemin is independent of SCD. Using genetic and bone marrow chimeric tools, we confirmed that TLR4 expressed in nonhematopoietic vascular tissues mediated this lethal type of acute lung injury. Respiratory failure was averted after the onset of ACS-like symptoms in sickle mice by treating them with recombinant hemopexin. Our results reveal a mechanism that helps to explain the pathogenesis of ACS, and we provide proof of principle for therapeutic strategies to prevent and treat this condition in mice.
急性胸部综合征 (ACS) 的预防和治疗是镰状细胞病 (SCD) 的一个主要临床关注点。然而,ACS 发病机制的根本机制仍不清楚。我们检验了这样一个假设,即血红蛋白分解产物血红素引发了诱导 ACS 的事件。低剂量血红素输注可导致转基因镰状细胞小鼠发生急性血管内溶血和细胞外血红素的自动扩增,但在镰状细胞表型的同窝仔鼠中则不会发生。镰状细胞小鼠出现了多种 ACS 典型症状,并迅速死亡。在血红素输注前进行 TLR4 药理学抑制和血影蛋白替代治疗可保护镰状细胞小鼠免受 ACS 发展的影响。在非镰状细胞小鼠中复制 ACS 样表型表明,由于细胞外血红素导致的肺损伤机制与 SCD 无关。使用基因和骨髓嵌合工具,我们证实了 TLR4 在非造血血管组织中的表达介导了这种致命类型的急性肺损伤。在镰状细胞小鼠出现 ACS 样症状后,用重组血影蛋白治疗可避免呼吸衰竭。我们的结果揭示了一种有助于解释 ACS 发病机制的机制,并为预防和治疗这种疾病的治疗策略提供了原理性证据。